New Stroke Drug, GLP-1 Advances, and Ebola Nears 11,000

Today's roundup spans six stories: a landmark FDA approval, two major GLP-1 trial readouts, an important negative cardiovascular trial, a novel pathogen update, and the continuing Ebola emergency in central Africa.

New Stroke Drug: FDA Approves Asundexian, the First Factor XIa Inhibitor

The US Food and Drug Administration approved asundexian (Sunharbo) on 9 November 2026, marking the first approval of a new class of anticoagulants — factor XIa (FXIa) inhibitors — for secondary stroke prevention. Developed by Bayer, Sunharbo is indicated for adults who have had a recent mild-to-moderate non-cardioembolic ischemic stroke or a high-risk transient ischaemic attack (TIA), taken alongside antiplatelet therapy.

The approval rests on the Phase 3 OCEANIC-STROKE trial, in which ischemic stroke occurred in 6.2% of patients on asundexian versus 8.4% on placebo — a 26% relative reduction over a median follow-up of 14.2 months. Critically, there was no increase in major bleeding by ISTH criteria, the safety signal that has historically limited how aggressively clinicians anticoagulate stroke patients. FXIa inhibitors work further upstream in the coagulation cascade than factor Xa or thrombin inhibitors, offering anticlotting effects with potentially less haemorrhagic risk. The FDA had granted fast-track and priority-review designations. China's NMPA had already approved the drug, and it is the first FXIa inhibitor to reach approval anywhere for this indication.

Orforglipron Cuts Sleep Apnea Severity by 44% in Phase 3

Eli Lilly reported Phase 3 ATTAIN-OSA data for Foundayo (orforglipron) on 9 November, showing that the oral GLP-1 receptor agonist significantly reduced obstructive sleep apnea (OSA) severity in two parallel year-long trials. In adults not using PAP therapy, the apnea-hypopnea index (AHI) — the standard measure of disease severity — fell by 43.8% on orforglipron versus 6.3% on placebo; 31.5% of participants reached remission or mild disease. In PAP users, the AHI reduction was 27.5% versus 3% on placebo.

The drug also reduced sleep apnea–specific hypoxic burden by 55.9% in non-PAP participants, alongside weight loss and falls in C-reactive protein, a marker of systemic inflammation. Lilly said it plans to submit an FDA application for the moderate-to-severe OSA indication in adults with obesity or overweight by the end of 2026. Orforglipron is a fully oral small-molecule GLP-1 agonist, avoiding injectable formulation entirely; it already carries FDA approval for type 2 diabetes and obesity. The adverse-event profile was dominated by gastrointestinal effects, with 12.2% discontinuations in the non-PAP group versus 3.8% on placebo.

Survodutide Passes Cardiovascular Safety Test — a First for Glucagon/GLP-1 Dual Agonists

Boehringer Ingelheim reported that survodutide — a glucagon/GLP-1 dual receptor agonist in development for obesity — met its primary cardiovascular safety endpoint in the SYNCHRONIZE-CVOT trial, the first dedicated cardiovascular outcomes trial for a drug in this class. The global, double-blind, placebo-controlled trial enrolled 5,530 adults with overweight or obesity and elevated cardiovascular risk. The five-point major adverse cardiovascular events (MACE) composite showed no excess risk versus placebo; the hazard ratio for three-point MACE was 0.84 (95% CI 0.60–1.18), a noninferiority finding.

Results were presented at the American Heart Association Scientific Sessions 2026 and simultaneously published in The Lancet on 9 November. The drug also delivered 13.7% mean weight loss at 72 weeks versus 2% on placebo. Boehringer said it plans regulatory submissions for survodutide in 2027.

An Important Negative Trial: Pelacarsen Lowers Lp(a) but Misses Clinical Outcomes

The HORIZON trial of pelacarsen — an RNA-targeted subcutaneous therapy aimed at lipoprotein(a), or Lp(a) — was published in NEJM and NEJM Evidence on 7 November with a result that challenges assumptions about Lp(a) as a clinical target. Pelacarsen reduced Lp(a) concentrations by approximately 78% in treated patients, a large and reproducible pharmacological effect. Despite this, the drug did not reduce the rate of MACE compared with placebo over the trial's follow-up period.

Lp(a) has long attracted interest as a heritable cardiovascular risk factor that standard LDL-lowering therapies do not address. High Lp(a) is associated with increased risks of heart attack, stroke, and aortic stenosis. The HORIZON result does not definitively close the door on the hypothesis — the trial's patient selection, duration, and baseline Lp(a) levels all matter — but it is a reminder that large effects on a biomarker do not automatically translate into clinical benefit. Other Lp(a)-targeting agents remain in Phase 3 development.

Ebola Bundibugyo Outbreak: 10,700 Cases, Spreading Beyond the DRC

The Bundibugyo-strain Ebola outbreak in the Democratic Republic of Congo has reached at least 10,741 confirmed cases and 5,230 deaths across eight provinces, according to ECDC data through 4 November. The most affected province remains Ituri, which accounts for 7,614 cases and 3,594 deaths from 28 of its 36 health zones. The outbreak has spread internationally: nine cases including two deaths have been confirmed in Kenya, and one case has been confirmed in Nigeria.

WHO Director-General Tedros Adhanom Ghebreyesus addressed a Member State briefing on 11 November, confirming that the outbreak remains a Public Health Emergency of International Concern (PHEIC). On 9 November, the US Centers for Disease Control and Prevention extended its suspension of entry for certain foreign nationals recently present in the DRC, Uganda, or South Sudan for a further 30 days; travellers boarding US-bound flights must attest that they have not been in the DRC in the previous 21 days. No cases have been confirmed in the United States; the risk to the general public outside sub-Saharan Africa and neighbouring countries remains low. For those travelling to affected regions or working in healthcare settings there, WHO and ECDC guidance on personal protective measures and isolation protocols applies.

Shamonda Virus: Europe's First Human Case Prompts a Joint Risk Assessment

France confirmed the first known human infection with Shamonda virus (SHAV) in October 2026 — a case that WHO and ECDC are still actively investigating. The patient, described as a severely immunocompromised older adult, was treated at the Hospices Civils de Lyon and died in early October; Shamonda virus was identified in the subsequent investigation. SHAV belongs to the Simbu serogroup within the Orthobunyavirus genus and had previously been detected only in animals. Transmission is thought to occur via Culicoides midges; the specific species involved in this case is still unknown.

Animal detections of SHAV have been recorded across much of western and central Europe — including Austria, Belgium, France, Germany, Ireland, Italy, the Netherlands, Spain, and Switzerland — during spring and summer 2026. No human-to-human transmission has been identified, and Santé publique France assessed the general population risk as low. ECDC and EFSA are preparing a joint risk assessment due 30 November 2026. For the Eastern Mediterranean, where Culicoides spp. are endemic and livestock densities are significant, the emergence of SHAV as a human pathogen — even in an immunocompromised host — warrants monitoring.

---

This article is a journalistic summary of published health and medicine news. It is not medical advice. If you have questions about your health or any change to your treatment, please consult a qualified clinician.